ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 476-500 of 1,000 matching filings.

Per page
25
Current page
20
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Nov 2022
Reporting date
01 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS

Filing date
26 Oct 2022
Reporting date
26 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON MESSINA PHASE III TRIAL

Filing date
25 Oct 2022
Reporting date
25 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER

Filing date
24 Oct 2022
Reporting date
24 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Oct 2022
Reporting date
03 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BOARD COMMITTEE CHANGES

Filing date
30 Sep 2022
Reporting date
30 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

KOSELUGO APPROVED IN JAPAN FOR NF1

Filing date
27 Sep 2022
Reporting date
27 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA

Filing date
27 Sep 2022
Reporting date
27 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ULTOMIRIS APPROVED IN EU FOR GMG

Filing date
23 Sep 2022
Reporting date
23 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER

Filing date
22 Sep 2022
Reporting date
22 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA

Filing date
21 Sep 2022
Reporting date
21 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT

Filing date
20 Sep 2022
Reporting date
20 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT

Filing date
16 Sep 2022
Reporting date
16 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP

Filing date
16 Sep 2022
Reporting date
16 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

EVUSHELD POSITIVE CHMP OPINION IN EU

Filing date
16 Sep 2022
Reporting date
16 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FORXIGA APPROVED IN CHINA FOR CKD

Filing date
06 Sep 2022
Reporting date
06 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER

Filing date
06 Sep 2022
Reporting date
06 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Sep 2022
Reporting date
01 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

EVUSHELD APPROVED FOR COVID-19 IN JAPAN

Filing date
30 Aug 2022
Reporting date
30 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF

Filing date
30 Aug 2022
Reporting date
30 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE

Filing date
30 Aug 2022
Reporting date
30 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ULTOMIRIS APPROVED IN JAPAN FOR GMG

Filing date
25 Aug 2022
Reporting date
25 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER

Filing date
25 Aug 2022
Reporting date
25 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER

Filing date
25 Aug 2022
Reporting date
25 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL

Filing date
16 Aug 2022
Reporting date
16 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .